Loading market dashboard
PureTech Health plc
PRTCHealthcareNASDAQUS
Loading disclosure news
News and disclosures filtered by period, publisher, and event group.
Select a headline to open the full news page in the app.
BOSTON--(BUSINESS WIRE)--PureTech to Showcase Deupirfenidone Program at the American Thoracic Society International Conference.
PureTech Health (LSE:PRTC, NASDAQ:PRTC, OTC:PTCHF, FRA:0VQ) told investors that its founded entity Seaport Therapeutics has priced an upsized US initial...
PureTech Health (LSE:PRTC, NASDAQ:PRTC, OTC:PTCHF, FRA:0VQ) told investors that its founded entity Seaport Therapeutics has priced an upsized US initial public offering at the top of its target range, putting the clinical-stage neuropsychiatry company on course to raise gross proceeds of $254.9 million. In London, PureTech shareholders saw the share price climb 9.56% to 139.8p.
PureTech Health plc (PRTC) Q4 2025 Earnings Call Transcript
BOSTON--(BUSINESS WIRE)--PureTech Announces Annual Results for Year Ended December 31, 2025.
BOSTON--(BUSINESS WIRE)--PureTech Announces Intention to Voluntarily Delist American Depositary Shares from Nasdaq and Concentrate Trading on the London Stock Exchange.
BOSTON--(BUSINESS WIRE)--PureTech Founded Entity Seaport Therapeutics Adds Intra-Cellular Therapies Founder and CEO, Dr. Sharon Mates, to its Board of Directors.
BOSTON--(BUSINESS WIRE)--PureTech Reports Positive Topline Data from Phase 1b Trial of LYT-200 in R/R High-Risk Myelodysplastic Syndrome & R/R Acute Myeloid Leukemia.
BOSTON--(BUSINESS WIRE)--PureTech Health: Notice of Results.
BOSTON--(BUSINESS WIRE)--PureTech Announces Publication of Phase 2b ELEVATE IPF Trial Results in The American Journal of Respiratory and Critical Care Medicine.
PureTech Health PLC Sponsored ADR (NASDAQ: PRTC - Get Free Report) was the recipient of a large growth in short interest during the month of March. As of March 13th, there was short interest totaling 11,335 shares, a growth of 140.8% from the February 26th total of 4,707 shares. Currently, 0.0% of the company's shares are
BOSTON--(BUSINESS WIRE)--PureTech Founded Entity Seaport Therapeutics Announces Publication in Science Translational Medicine Featuring GlyphAllo (SPT-300).
